Use of Janus kinase inhibitors in atopic dermatitis - an update

被引：5

作者：

Dhar, Sandipan ^{[1
]}

Datta, Shreya ^{[2
]}

De, Abhishek ^{[2
,3
]}

机构：

[1] Inst Child Hlth, Dept Pediat Dermatol, Kolkata, W Bengal, India

[2] Calcutta Natl Med Coll, Dept Dermatol, Kolkata, W Bengal, India

[3] CNMC, Dept Dermatol, Kolkata, India

来源：

INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY | 2024年 / 90卷 / 03期

关键词：

Janus kinase inhibitors; atopic dermatitis; abrocitinib; upadacitinib; ruxolitinib; baricitinib; ADULT PATIENTS; DOUBLE-BLIND; MODERATE; MULTICENTER; BIOLOGICS; EFFICACY; PHASE-3; SAFETY;

D O I：

10.25259/IJDVL_14_2023

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Atopic dermatitis is among the cutaneous inflammatory disorders whose pathophysiology is thought to be influenced by the JAK-STAT intracellular signalling system. The effectiveness of systemic and topical Janus kinase (JAK) inhibitors in the treatment of atopic dermatitis has been shown in clinical trials and case studies. At present, oral abrocitinib (Cibinqo), oral upadacitinib (Rinvoq), oral baricitinib (Olumiant) and topical ruxolitinib (Opzelura) have approval from the US-FDA for their use in the treatment of atopic dermatitis. The efficacy and safety of oral and topical Janus kinase inhibitors for the treatment of atopic dermatitis have been reviewed in this article.

引用

页码：311 / 317

页数：7

共 50 条

[31] Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
Sood, Siddhartha
Bagit, Ahmed
Heung, Martin
Maliyar, Khalad
Abduelmula, Abrabim
Sachdeva, Muskaan
Georgakopoulos, Jorge R.
Mufti, Asfandyar
Prajapati, Vimal H.
Yeung, Jensen
JAAD INTERNATIONAL, 2024, 16 : 31 - 33
[32] The role of Janus kinase signaling in the pathology of atopic dermatitis
Guttman-Yassky, Emma
Irvine, Alan D.
Brunner, Patrick M.
Kim, Brian S.
Boguniewicz, Mark
Parmentier, Julie
Platt, Andrew M.
Kabashima, Kenji
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 152 (06) : 1394 - 1404
[33] Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience
Lauffer, Felix
Biedermann, Tilo
DERMATOLOGIE, 2022, 73 (07): : 520 - 528
[34] Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis
Narla, Shanthi
Silverberg, Jonathan I.
DERMATITIS, 2024, 35 : S24 - S38
[35] Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis
Ebata, Toshiya
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (02) : 165 - 165
[36] The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis
Arora, Charan Jeet
Khattak, Fakhre Alam
Yousafzai, Mohammad Tahir
Ibitoye, Bukola Mary
Shumack, Stephen
DERMATOLOGIC THERAPY, 2020, 33 (04)
[37] Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses
Garcia-Melendo, C.
Cubiro, X.
Puig, L.
ACTAS DERMO-SIFILIOGRAFICAS, 2021, 112 (07): : 586 - 600
[38] Correction to: JAK Inhibitors for Atopic Dermatitis: An Update
Helen He
Emma Guttman-Yassky
American Journal of Clinical Dermatology, 2019, 20 : 193 - 193
[39] Topical Janus kinase inhibitors in the treatment of atopic eczema
Doyle, M.
ALLERGY, 2023, 78
[40] Comparative safety analysis of antiinterleukin-4/interleukin-13 inhibitors and Janus Kinase inhibitors in atopic dermatitis
Bao, Aaron
Su, Hsing-Jou
Wan, Joy
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 768 - 771

← 1 2 3 4 5 →